MacroGenics enters collaboration and license agreement with Janssen to develop MGD011
MacroGenics announced a global collaboration and license agreement for MGD011 with Janssen Biotech. This product candidate incorporates MacroGenics' proprietary platform for Dual-Affinity Re-Targeting (DART®) to simultaneously target CD19 and CD3 for potential treatment of B-cell malignancies. December 22, 2014